A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.

Trial Details

NCT ID
NCT05984147
Phase
PHASE1
Sponsor
Aurigene Discovery Technologies Limited
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • AUR108
Locations (sample)
  • Visakhapatnam, Andhra Pradesh, India|17.68009,83.20161
  • Chandigarh, Chandigarh, India|30.73629,76.7884
  • Ahmedabad, Gujarat, India|23.02579,72.58727
  • Ahmedabad, Gujarat, India|23.02579,72.58727
  • Ahmedabad, Gujarat, India|23.02579,72.58727

Key Eligibility Criteria

  • Males or females ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1
  • Acceptable bone marrow and organ function at screening as described below:
  • ANC ≥ 1000/μL (without WBC growth factor support)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →